. Au-cours-du-suivi, 28 patients ont présenté une récidive post-opératoire : 3 locorégionales et 25 métastatiques. La médiane de survie sans récidive était de 17, pp.1-38

R. Siegel, K. Miller, and A. Jemal, Cancer statistics, 2017, CA: A Cancer Journal for Clinicians, vol.91, issue.suppl 3, pp.7-30, 2017.
DOI : 10.1016/j.ypmed.2016.08.015

A. Khorana, P. Mangu, J. Berlin, A. Engebretson, T. Hong et al., Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, vol.34, issue.21, pp.2541-56, 2016.
DOI : 10.1200/JCO.2016.67.5553

M. Al-hawary, I. Francis, S. Chari, E. Fishman, D. Hough et al., Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association, Gastroenterology, vol.146, issue.1, pp.291-304, 2014.
DOI : 10.1053/j.gastro.2013.11.004

P. Pisters, J. Lee, J. Vauthey, C. Charnsangavej, and D. Evans, Laparoscopy in the staging of pancreatic cancer, British Journal of Surgery, vol.ii, issue.3, pp.325-362, 2001.
DOI : 10.1016/S0140-6736(69)92326-5

Z. Zhao, J. He, G. Tan, H. Wang, and K. Li, Laparoscopy and laparoscopic ultrasonography in judging the resectability of pancreatic head cancer, Hepatobiliary Pancreat Dis Int HBPD INT. nov, vol.2, issue.4, pp.609-620, 2003.

G. Varadhachary, E. Tamm, J. Abbruzzese, H. Xiong, C. Crane et al., Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy, Annals of Surgical Oncology, vol.9, issue.8
DOI : 10.2214/ajr.178.4.1780821

M. Katz, P. Pisters, D. Evans, C. Sun, J. Lee et al., Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease, Journal of the American College of Surgeons, vol.206, issue.5, pp.833-846, 2008.
DOI : 10.1016/j.jamcollsurg.2007.12.020

M. Tempero, M. Malafa, M. Hawary, H. Asbun, A. Bain et al., Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network, vol.15, issue.8, pp.1028-61, 2017.
DOI : 10.6004/jnccn.2017.0131

D. Pandey, Redefining the R1 resection in pancreatic cancer, Br J Surg, vol.93, pp.1232-1237, 2006.

H. Oettle, P. Neuhaus, A. Hochhaus, J. Hartmann, K. Gellert et al., Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer, JAMA, vol.310, issue.14, pp.1473-81, 2013.
DOI : 10.1001/jama.2013.279201

URL : http://jama.jamanetwork.com/data/journals/jama/927990/joi130069.pdf

B. Rau, K. Moritz, S. Schuschan, G. Alsfasser, F. Prall et al., R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use, Surgery, vol.152, issue.3, pp.103-111, 2012.
DOI : 10.1016/j.surg.2012.05.015

S. Yamada, T. Fujii, H. Sugimoto, S. Nomoto, S. Takeda et al., Aggressive Surgery for Borderline Resectable Pancreatic Cancer, Pancreas, vol.42, issue.6, pp.1004-1014, 2013.
DOI : 10.1097/MPA.0b013e31827b2d7c

J. Delpero, J. Boher, A. Sauvanet, L. Treut, Y. Sa-cunha et al., Pancreatic Adenocarcinoma with Venous Involvement: Is Up-Front Synchronous Portal-Superior Mesenteric Vein Resection Still Justified? A Survey of the Association Fran??aise de Chirurgie, Annals of Surgical Oncology, vol.19, issue.suppl 3, pp.1874-83, 2015.
DOI : 10.1245/s10434-011-2110-8

H. Haeno, M. Gonen, M. Davis, J. Herman, C. Iacobuzio-donahue et al., Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell, pp.362-75, 2012.

T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud et al., FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1842, 2011.
DOI : 10.1056/NEJMoa1011923

URL : https://hal.archives-ouvertes.fr/hal-00598658

V. Hoff, D. Ervin, T. Arena, F. Chiorean, E. Infante et al., Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, New England Journal of Medicine, vol.369, issue.18, pp.1691-703, 2013.
DOI : 10.1056/NEJMoa1304369

K. Tang, W. Lu, W. Qin, and Y. Wu, Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages, Pancreatology, vol.16, issue.1, pp.28-37, 2016.
DOI : 10.1016/j.pan.2015.11.007

F. Petrelli, A. Coinu, K. Borgonovo, M. Cabiddu, M. Ghilardi et al., FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer, Pancreas, vol.44, issue.4, pp.515-536, 2015.
DOI : 10.1097/MPA.0000000000000314

J. Delpero, P. Bachellier, N. Regenet, L. Treut, Y. Paye et al., Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens, HPB, vol.16, issue.1, pp.20-33, 2014.
DOI : 10.1111/hpb.12061

D. Åkerberg, D. Ansari, and R. Andersson, Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas, World Journal of Gastroenterology, vol.22, issue.28, pp.6424-6457, 2016.
DOI : 10.1016/j.gassur.2006.09.008

D. Pietrasz, L. Marthey, M. Wagner, J. Blanc, C. Laurent et al., Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort, Annals of Surgical Oncology, vol.11, issue.9, pp.1196-205, 2015.
DOI : 10.1016/S1470-2045(10)70172-8

B. Boone, S. J. Zenati, M. Hogg, M. Singhi, A. Bartlett et al., Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma, Annals of Surgical Oncology, vol.11, issue.13, pp.4351-4359, 2014.
DOI : 10.1111/j.1477-2574.2009.00110.x

R. Maréchal, J. Bachet, J. Mackey, C. Dalban, P. Demetter et al., Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma, Gastroenterology, vol.143, issue.3, pp.664-674, 2012.
DOI : 10.1053/j.gastro.2012.06.006

M. Hidalgo, C. Plaza, M. Musteanu, P. Illei, C. Brachmann et al., SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial, Clinical Cancer Research, vol.21, issue.21, pp.4811-4819, 2015.
DOI : 10.1158/1078-0432.CCR-14-3222

M. Capello, M. Lee, H. Wang, I. Babel, M. Katz et al., Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma, JNCI: Journal of the National Cancer Institute, vol.19, issue.5, 2015.
DOI : 10.1158/1078-0432.CCR-12-1184

D. Li, J. Morris, J. Liu, M. Hassan, R. Day et al., Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer, JAMA, vol.301, issue.24, pp.2553-62, 2009.
DOI : 10.1001/jama.2009.886

D. Hanahan and R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011.
DOI : 10.1016/j.cell.2011.02.013

F. Balkwill and A. Mantovani, Inflammation and cancer: back to Virchow?, The Lancet, vol.357, issue.9255, pp.539-584, 2001.
DOI : 10.1016/S0140-6736(00)04046-0

F. Salazar-onfray, M. López, and A. Mendoza-naranjo, Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape, Cytokine & Growth Factor Reviews, vol.18, issue.1-2, pp.171-82, 2007.
DOI : 10.1016/j.cytogfr.2007.01.015

P. Yu and Y. Fu, Tumor-infiltrating T lymphocytes: friends or foes?, Laboratory Investigation, vol.5, issue.Part 2, pp.231-276, 2006.
DOI : 10.1038/ni1029

URL : http://www.nature.com/labinvest/journal/v86/n3/pdf/3700389a.pdf

K. Inman, A. Francis, and N. Murray, Complex role for the immune system in initiation and progression of pancreatic cancer, World Journal of Gastroenterology, vol.20, issue.32, pp.11160-81, 2014.
DOI : 10.1038/ni.1791

G. Bellone, A. Turletti, E. Artusio, K. Mareschi, A. Carbone et al., Tumor-Associated Transforming Growth Factor-?? and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients, The American Journal of Pathology, vol.155, issue.2, pp.537-584, 1999.
DOI : 10.1016/S0002-9440(10)65149-8

F. Romano, F. Uggeri, S. Crippa, D. Stefano, G. Scotti et al., Immunodeficiency in different histotypes of radically operable gastrointestinal cancers, J Exp Clin Cancer Res CR. juin, vol.23, issue.2, pp.195-200, 2004.

W. Von-bernstorff, M. Voss, S. Freichel, A. Schmid, I. Vogel et al., Systemic and local immunosuppression in pancreatic cancer patients, Clin Cancer Res Off J Am Assoc Cancer Res. mars, vol.7, issue.3, pp.925-932, 2001.

D. Mcmillan, Systemic inflammation, nutritional status and survival in patients with cancer, Current Opinion in Clinical Nutrition and Metabolic Care, vol.12, issue.3, pp.223-229, 2009.
DOI : 10.1097/MCO.0b013e32832a7902

D. Mcmillan, M. Elahi, N. Sattar, W. Angerson, J. Johnstone et al., Measurement of the Systemic Inflammatory Response Predicts Cancer-Specific and Non-Cancer Survival in Patients With Cancer, Nutrition and Cancer, vol.41, issue.1-2, pp.64-73, 2001.
DOI : 10.1080/01635581.2001.9680613

A. Fleck, G. Raines, F. Hawker, J. Trotter, P. Wallace et al., INCREASED VASCULAR PERMEABILITY: A MAJOR CAUSE OF HYPOALBUMINAEMIA IN DISEASE AND INJURY, The Lancet, vol.325, issue.8432, pp.781-785, 1985.
DOI : 10.1016/S0140-6736(85)91447-3

C. Gabay and I. Kushner, Acute-Phase Proteins and Other Systemic Responses to Inflammation, New England Journal of Medicine, vol.340, issue.6, pp.448-54, 1999.
DOI : 10.1056/NEJM199902113400607

R. Zahorec, Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill, Bratisl Lek Listy, vol.102, issue.1, pp.5-14, 2001.

M. Alexandrakis, F. Passam, I. Moschandrea, A. Christophoridou, C. Pappa et al., Levels of Serum Cytokines and Acute Phase Proteins in Patients With Essential and Cancer-Related Thrombocytosis, American Journal of Clinical Oncology, vol.26, issue.2, pp.135-175, 2003.
DOI : 10.1097/00000421-200304000-00007

H. Pinedo, H. Verheul, D. Amato, R. Folkman, and J. , Involvement of platelets in tumour angiogenesis? Lancet Lond Engl, pp.1775-1782, 1998.

J. Falconer, K. Fearon, C. Plester, J. Ross, and D. Carter, Cytokines, the Acute-Phase Response, and Resting Energy Expenditure in Cachectic Patients with Pancreatic Cancer, Annals of Surgery, vol.219, issue.4
DOI : 10.1097/00000658-199404000-00001

D. Mcmillan, H. Scott, W. Watson, T. Preston, R. Milroy et al., Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients, Nutrition and Cancer, vol.12, issue.2, pp.101-106, 1998.
DOI : 10.1016/0899-9007(95)00078-X

O. Gorman, P. Mcmillan, D. Mcardle, and C. , Longitudinal Study of Weight, Appetite, Performance Status, and Inflammation in Advanced Gastrointestinal Cancer, Nutrition and Cancer, vol.35, issue.2, pp.127-136, 1999.
DOI : 10.1207/S15327914NC352_5

L. Forrest, D. Mcmillan, C. Mcardle, W. Angerson, and D. Dunlop, Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer, British Journal of Cancer, vol.71, issue.Suppl 4, pp.1028-1058, 2003.
DOI : 10.1038/bjc.1995.212

D. Mcmillan, J. Crozier, K. Canna, W. Angerson, and C. Mcardle, Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer, International Journal of Colorectal Disease, vol.47, issue.8 Suppl, pp.881-887, 2007.
DOI : 10.7326/0003-4819-133-8-200010170-00015

A. Crumley, D. Mcmillan, M. Mckernan, A. Mcdonald, and R. Stuart, Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer, British Journal of Cancer, vol.87, issue.Suppl 1, pp.637-678, 2006.
DOI : 10.1038/sj.bjc.6600466

J. Szkandera, M. Stotz, G. Absenger, T. Stojakovic, H. Samonigg et al., Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients, British Journal of Cancer, vol.196, issue.1, pp.183-191, 2014.
DOI : 10.1007/s12032-012-0226-8

J. Falconer, K. Fearon, J. Ross, R. Elton, S. Wigmore et al., Acute-phase protein response and survival duration of patients with pancreatic cancer, Cancer, vol.72, issue.8, pp.2077-82, 1995.
DOI : 10.1038/bjc.1994.93

H. Imaoka, N. Mizuno, K. Hara, S. Hijioka, M. Tajika et al., Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer, Pancreas, vol.45, issue.2, pp.211-218, 2016.
DOI : 10.1097/MPA.0000000000000446

J. Yang, Z. Hu, W. Shi, T. Deng, S. He et al., Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis, World Journal of Gastroenterology, vol.21, issue.9, pp.2807-2822, 2015.
DOI : 10.1038/bjc.2012.292

Q. Qi, Y. Geng, M. Sun, P. Wang, and Z. Chen, Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer, Pancreatology, vol.15, issue.2, pp.145-50, 2015.
DOI : 10.1016/j.pan.2014.12.004

D. Wang, H. Luo, M. Qiu, Z. Wang, D. Zhang et al., Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer, Medical Oncology, vol.173, issue.5, pp.3092-100, 2012.
DOI : 10.1093/aje/kwq437

S. Yamada, T. Fujii, N. Yabusaki, K. Murotani, N. Iwata et al., Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer, Medicine, vol.95, issue.18, p.3582, 2016.
DOI : 10.1097/MD.0000000000003582

P. Sanjay, R. De-figueiredo, H. Leaver, S. Ogston, C. Kulli et al., Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma, JOP J Pancreas. 10 mars, vol.13, issue.2, pp.199-204, 2012.

N. Jamieson, P. Glen, D. Mcmillan, C. Mckay, A. Foulis et al., Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas, British Journal of Cancer, vol.221, issue.2B, pp.21-24, 2005.
DOI : 10.1097/00000658-199506000-00011

N. Jamieson, S. Denley, J. Logue, D. Mackenzie, A. Foulis et al., A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma, Annals of Surgical Oncology, vol.88, issue.8, pp.2318-2346, 2011.
DOI : 10.1007/s00109-009-0547-z

L. Torre, M. Nigri, G. Cavallini, M. Mercantini, P. Ziparo et al., The Glasgow Prognostic Score as a Predictor of Survival in Patients with Potentially Resectable Pancreatic Adenocarcinoma, Annals of Surgical Oncology, vol.238, issue.1, pp.2917-2940, 2012.
DOI : 10.1245/s10434-008-0148-z

Q. Ben, A. W. Wang, L. Wang, W. Yu, L. Yuan et al., Validation of the pretreatment neutrophillymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma, Pancreas. avr, vol.44, issue.3, pp.471-478, 2015.

G. Garcea, N. Ladwa, C. Neal, M. Metcalfe, A. Dennison et al., Preoperative Neutrophil-to-Lymphocyte Ratio (NLR) is Associated with Reduced Disease-free Survival Following Curative Resection of Pancreatic Adenocarcinoma, World Journal of Surgery, vol.129, issue.4, pp.868-72, 2011.
DOI : 10.1207/S15327914NC352_2

R. Smith, L. Bosonnet, M. Raraty, R. Sutton, J. Neoptolemos et al., Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma, The American Journal of Surgery, vol.197, issue.4, pp.466-72, 2009.
DOI : 10.1016/j.amjsurg.2007.12.057

I. Bhatti, O. Peacock, G. Lloyd, M. Larvin, and R. Hall, Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio, The American Journal of Surgery, vol.200, issue.2, pp.197-203, 2010.
DOI : 10.1016/j.amjsurg.2009.08.041

Y. Shirai, H. Shiba, T. Sakamoto, T. Horiuchi, K. Haruki et al., Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection, Surgery, vol.158, issue.2, pp.360-365, 2015.
DOI : 10.1016/j.surg.2015.03.043

S. Asari, I. Matsumoto, H. Toyama, M. Shinzeki, T. Goto et al., Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios, Surgery Today, vol.13, issue.5, pp.583-92, 2016.
DOI : 10.1080/13651820701774891

M. Jamal, S. Doi, E. Simoneau, A. Khalil, J. Hassanain et al., Unresectable pancreatic adenocarcinoma: do we know who survives?, HPB, vol.12, issue.8, pp.561-567, 2010.
DOI : 10.1111/j.1477-2574.2010.00220.x

URL : https://doi.org/10.1111/j.1477-2574.2010.00220.x

J. Bachmann, M. Heiligensetzer, H. Krakowski-roosen, M. Büchler, H. Friess et al., Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer, Journal of Gastrointestinal Surgery, vol.45, issue.7, pp.1193-201, 2008.
DOI : 10.1016/j.ejso.2007.01.022

K. Fearon, F. Strasser, S. Anker, I. Bosaeus, E. Bruera et al., Definition and classification of cancer cachexia: an international consensus, The Lancet Oncology, vol.12, issue.5, pp.489-95, 2011.
DOI : 10.1016/S1470-2045(10)70218-7

R. Baumgartner, K. Koehler, D. Gallagher, L. Romero, S. Heymsfield et al., Epidemiology of Sarcopenia among the Elderly in New Mexico, American Journal of Epidemiology, vol.147, issue.8, pp.755-63, 1998.
DOI : 10.1093/oxfordjournals.aje.a009520

W. Shen, M. Punyanitya, Z. Wang, D. Gallagher, M. St-onge et al., Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image, Journal of Applied Physiology, vol.97, issue.6, pp.2333-2341, 1985.
DOI : 10.1038/oby.2003.53

URL : http://jap.physiology.org/content/jap/97/6/2333.full.pdf

S. Shachar, G. Williams, H. Muss, and T. Nishijima, Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review, European Journal of Cancer, vol.57, pp.58-67, 1990.
DOI : 10.1016/j.ejca.2015.12.030

C. Prado, J. Lieffers, L. Mccargar, T. Reiman, M. Sawyer et al., Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, The Lancet Oncology, vol.9, issue.7, pp.629-664, 2008.
DOI : 10.1016/S1470-2045(08)70153-0

B. Tan, L. Birdsell, L. Martin, V. Baracos, and K. Fearon, Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer, Clinical Cancer Research, vol.15, issue.22, pp.6973-6982, 2009.
DOI : 10.1158/1078-0432.CCR-09-1525

Y. Choi, D. Oh, T. Kim, K. Lee, S. Han et al., Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index, PLOS ONE, vol.67, issue.10, p.139749, 2015.
DOI : 10.1371/journal.pone.0139749.s003

P. Peng, O. Hyder, A. Firoozmand, P. Kneuertz, R. Schulick et al., Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma, Journal of Gastrointestinal Surgery, vol.91, issue.4, pp.1478-86, 2012.
DOI : 10.3945/ajcn.2010.28608C

G. Ninomiya, T. Fujii, S. Yamada, N. Yabusaki, K. Suzuki et al., Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study, International Journal of Surgery, vol.39, pp.45-51, 2017.
DOI : 10.1016/j.ijsu.2017.01.075

I. Matsumoto, Y. Murakami, M. Shinzeki, S. Asari, T. Goto et al., Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study, Pancreatology, vol.15, issue.6, pp.674-80, 2015.
DOI : 10.1016/j.pan.2015.09.008

A. Cooper, R. Slack, D. Fogelman, H. Holmes, M. Petzel et al., Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer, Annals of Surgical Oncology, vol.20, issue.31, pp.2416-2439, 2015.
DOI : 10.1245/s10434-013-2886-9

M. Kiliç, E. Göçmen, M. Tez, T. Ertan, M. Keskek et al., Value of preoperative serum CA 19- 9 levels in predicting resectability for pancreatic cancer, Can J Surg J Can Chir. août, vol.49, issue.4, pp.241-245, 2006.

N. Alexakis, I. Gomatos, S. Sbarounis, K. Toutouzas, S. Katsaragakis et al., High serum CA 19-9 but not tumor size should select patients for staging laparoscopy in radiological resectable pancreas head and peri-ampullary cancer, European Journal of Surgical Oncology (EJSO), vol.41, issue.2, pp.265-274, 2015.
DOI : 10.1016/j.ejso.2014.09.006

F. Petrelli, A. Inno, S. Barni, A. Ghidini, R. Labianca et al., Borderline resectable pancreatic cancer: More than an anatomical concept, Digestive and Liver Disease, vol.49, issue.2, pp.223-229, 2017.
DOI : 10.1016/j.dld.2016.11.010

O. Zalite, I. Zykus, R. , F. Gonzalez, M. Saygili et al., Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review, Pancreatology, vol.15, issue.1, pp.19-24, 2015.
DOI : 10.1016/j.pan.2014.11.006

H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr et al., Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer, JAMA, vol.297, issue.3, pp.267-77, 2007.
DOI : 10.1001/jama.297.3.267

M. Katz, J. Fleming, P. Bhosale, G. Varadhachary, J. Lee et al., Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators, Cancer, vol.364, issue.23, pp.5749-56, 2012.
DOI : 10.1056/NEJMoa1011923

C. Ferrone, G. Marchegiani, T. Hong, D. Ryan, V. Deshpande et al., Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer, Annals of Surgery, vol.261, issue.1, pp.12-19, 2015.
DOI : 10.1097/SLA.0000000000000867